Liraglutide

Also known as: Victoza, Saxenda

Weight LossFDA APPROVED

Clinical Status

FDA Approved — Type 2 diabetes (Victoza) and weight management (Saxenda).

Mechanism of Action

GLP-1 receptor agonist with 97% homology to native GLP-1. Binds to albumin for extended half-life. Slows gastric emptying, suppresses appetite via hypothalamic action, and enhances glucose-dependent insulin secretion.

Dosing Defaults

Dose

1.8-3.0 mg daily

Frequency

1x daily

Administration

Subcutaneous injection

Timing

Same time each day

Food

with or without

Duration

Long-term / chronic use

Dose range: 0.6-3.0 mg daily

Daily injection at consistent time maintains steady drug levels.

Side Effects

•Nausea
•Vomiting
•Diarrhea
•Constipation
•Headache
•Hypoglycemia
•Pancreatitis
•Gallbladder disease

Contraindications & Warnings

⚠Personal/family history of medullary thyroid carcinoma
⚠MEN 2 syndrome

•Not medical advice
•BOXED WARNING: Thyroid C-cell tumors

Compare

Compare Liraglutide with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Liraglutide dose.

Open Calculator

Related Weight Loss Peptides

Semaglutide

FDA APPROVED

Weight Loss

GLP-1 receptor agonist. FDA-approved for type 2 diabetes and weight management.

Tirzepatide

FDA APPROVED

Weight Loss

Dual GLP-1/GIP receptor agonist. FDA-approved for T2D and weight management.

Retatrutide

PHASE 3

Weight Loss

Triple receptor agonist (GLP-1/GIP/Glucagon). Most potent weight loss peptide in trials.

AOD-9604

PHASE 2

Weight Loss

GH fragment for fat metabolism. Does NOT produce typical HGH side effects.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.